Oxford, UK – 31 October 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy
Oxford BioMedica notes the CTL019 MAA submission to the EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Oxford, UK – 06 November 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today not
Kymriah (tisagenlecleucel, formerly CTL019) receives positive CHMP opinion for the treatment of two aggressive blood cancers, marking important milestone for patients in Europe
London, UK - 29 June 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell
The LentiVector® platform is the only commercially approved lentiviral-based gene delivery system.
Oxford BioMedica has developed packaging and inducible producer cell lines that enable a simplified and scalable manufacturing process whil